Search | Clinical Trials Finder

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Interferon beta-1a, Alemtuzumab 12 mg, Alemtuzumab 24 mg; Biological
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2010
U.S. locations: 31
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • Berkeley, California + 27 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: BAY86-5046_Interferon-beta-1b; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 27
States / cities: Many Locations, Alabama • Many Locations, California • Many Locations, Colorado + 24 more

Conditions: Multiple Sclerosis
Interventions: ofatumumab with PRF, ofatumumab with AI; Combination Product
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 13
States / cities: Fullerton, California • Aurora, Colorado • Basalt, Colorado + 9 more

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: BG00002 (natalizumab), interferon beta-1a, glatiramer acetate; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 19
States / cities: Cullman, Alabama • Phoenix, Arizona • Fort Collins, Colorado + 16 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Natalizumab (Tysabri); Drug
Lead sponsor: Cornerstone Health Care, PA; Other
Eligibility: 18 Years to 65 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 3
States / cities: Patchogue, New York • High Point, North Carolina • Portland, Oregon

Conditions: Multiple Sclerosis
Interventions: Glatiramer Acetate (GTR), Glatiramer Acetate (Copaxone®), Placebo; Drug
Lead sponsor: Synthon BV; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 794 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 7
States / cities: Irvine, California • Port Charlotte, Florida • Sunrise, Florida + 4 more

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: Helminth ova; Biological
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 50 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: Glatiramer acetate (GA), Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 37
States / cities: Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 32 more

Conditions: Multiple Sclerosis
Interventions: ACT-128800 Dose 1, Placebo, ACT-128800 Dose 2, ACT-128800 Dose 3; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 25
States / cities: Scottsdale, Arizona • Tucson, Arizona • Sacramento, California + 22 more

Conditions: Relapsing Multiple Sclerosis, Clinically Isolated Syndrome, Relapsing-remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Interventions: Not listed
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 326 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Relapsing-Remitting Multiple Sclerosis
Interventions: Glatiramer acetate; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2018
U.S. locations: 11
States / cities: Los Angeles, California • New Haven, Connecticut • Baltimore, Maryland + 7 more

Conditions: Relapsing-remitting Multiple Sclerosis, Clinically Isolated Syndrome
Interventions: Not listed
Lead sponsor: Providence Multiple Sclerosis Center; Other
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Transcranial Direct Current Stimulation, Sham transcranial direct current stimulation; Device
Lead sponsor: The University of Texas at Dallas; Other
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Richardson, Texas

Conditions: Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Interventions: Tetanus, diphtheria, and acellular pertussis vaccine, Pneumococcal polysaccharide vaccine, Seasonal influenza vaccine; Biological
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 29
States / cities: Palo Alto, California • Colorado Springs, Colorado • Southington, Connecticut + 26 more

Conditions: Relapsing-remitting Multiple Sclerosis
Interventions: Vatelizumab; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 6
States / cities: Cullman, Alabama • Fort Collins, Colorado • Ormond Beach, Florida + 3 more

Conditions: Multiple Sclerosis (MS) - Relapsing-remitting
Interventions: Ublituximab, Other disease modifying therapies; Drug · Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Relapsing Multiple Sclerosis, Clinically Isolated Syndrome, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Interventions: Not listed
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Relapsing-Remitting Multiple Sclerosis
Interventions: Not listed
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Foxborough, Massachusetts

Conditions: Multiple Sclerosis
Interventions: Tysabri; Drug
Lead sponsor: University at Buffalo; Other
Eligibility: 18 Years to 65 Years
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Multiple Sclerosis, Neurogenic Bladder
Interventions: vaginal estriol; Drug
Lead sponsor: Texas Tech University Health Sciences Center; Other
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Multiple Sclerosis, Relapsing-Remitting, Fatigue
Interventions: TENOFOVIR ALAFENAMIDE FUMARATE 25 Mg ORAL TABLET [VEMLIDY], Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
Interventions: Acute Intermittent Hypoxia, Sham Acute Intermittent Hypoxia; Other
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 18 Years to 75 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Relapsing-Remitting Multiple Sclerosis
Interventions: Cladribine, Placebo; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 867 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 17
States / cities: Boulder, Colorado • Atlanta, Georgia • Chicago, Illinois + 14 more

Conditions: Relapsing-Remitting Multiple Sclerosis
Interventions: Tovaxin Autologous T cell vaccine, Placebo; Biological
Lead sponsor: Opexa Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 33
States / cities: Cullman, Alabama • Phoenix, Arizona • Berkeley, California + 29 more

Search by objective public record fields.

A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis

Real-World Betaseron Health Economic Outcomes Study for Relapsing Forms of Multiple Sclerosis

A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients

Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis

NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness

Efficacy and Safety of GTR in Comparison to Copaxone®

Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple Sclerosis

A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo

Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis

Study to Assess Changes in Immunoglobulins in Patients With Relapsing Multiple Sclerosis Treated With Anti-CD20 Therapies

Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness

Safety/Effectiveness of Adding Monthly Dexamethasone to Weekly Avonex for MS

Treatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial Direct Current Stimulation

Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy

Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839

Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosis

A Study to Assess the Effectiveness and Safety of Mayzent in Chinese Patients With Relapsing Forms of Multiple Sclerosis

Retrospective Study to Determine Effect of Rebif and Tecfidera on Infections and Lymphocytes

Effect of Tysabri in Patients With Relapsing-Remitting Multiple Sclerosis: A Follow-up Magnetization Transfer Imaging (MTI) Study

Vaginal Estriol in Multiple Sclerosis

Tenofovir Alafenamide for Treatment of Symptoms and Neuroprotection in Relapsing Remitting Multiple Sclerosis

Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS

CLARITY Extension Study

Autologous T Cell Vaccine (TCV) for Multiple Sclerosis